bluebird, which develops gene and cell therapies for severe genetic diseases and T cell-based immunotherapies for cancer, is making investments in manufacturing infrastructure to advance its clinical and potentially commercial production. The company plans to hire about 50 employees to work in the new site, at 1733 T.W. Alexander Drive.
Biotechnology company bluebird bio will open its third U.S. site at a 125,000-square-foot manufacturing facility in Durham.
“We are working together with them and with internal manufacturing to execute on this strategy,” Adams said. “Both pieces are essential parts.”
Renovation work on the existing building at the site will begin in early 2018.
The North Carolina Biotechnology Center’s Economic Development Award program has committed to financially support bluebird when it reaches specific job creation targets, Adams said.